Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Cash from Operations (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Cash from Operations for 12 consecutive years, with 16353000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 41.87% year-over-year to 16353000.0, compared with a TTM value of 52244000.0 through Sep 2025, down 42.05%, and an annual FY2024 reading of 49056000.0, down 59.9% over the prior year.
  • Cash from Operations was 16353000.0 for Q3 2025 at Avalo Therapeutics, down from 11390000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 5726000.0 in Q3 2022 and bottomed at 19187000.0 in Q2 2021.
  • Average Cash from Operations over 5 years is 11293631.58, with a median of 11527000.0 recorded in 2024.
  • The sharpest move saw Cash from Operations skyrocketed 135.15% in 2022, then plummeted 443.89% in 2024.
  • Year by year, Cash from Operations stood at 17099000.0 in 2021, then skyrocketed by 76.96% to 3940000.0 in 2022, then grew by 29.8% to 2766000.0 in 2023, then tumbled by 443.89% to 15044000.0 in 2024, then decreased by 8.7% to 16353000.0 in 2025.
  • Business Quant data shows Cash from Operations for AVTX at 16353000.0 in Q3 2025, 11390000.0 in Q2 2025, and 9457000.0 in Q1 2025.